摘要
目的对上海市2004—2014年艾滋病抗病毒治疗效果及其影响因素进行分析评价。方法选择艾滋病综合防治信息系统中2004—2014年在上海市接受抗病毒治疗的3 939例艾滋病病毒感染者及病人进行回顾性分析。结果 3 939例研究对象中,男性占90.2%,平均年龄为(38.4±12.5)岁,抗病毒治疗方案以依非韦伦+齐多夫定+拉米夫定为主(占35.8%)。基线CD4+T淋巴细胞计数平均为(199.2±142.9)个/mm^3,治疗后CD4^+T淋巴细胞计数平均为(457.2±211.9)个/mm^3,平均增长258.0个/mm^3,治疗前后差异有统计学意义(P<0.001)。女性、治疗时间较长、异性性传播、基线CD_4^+T淋巴细胞计数<350个/mm^3的对象,CD_4^+T淋巴细胞计数在治疗后增长相对较多。3 939例接受抗病毒治疗的病例中,93.5%达到病毒完全抑制。随着治疗时间的增加,病毒完全抑制率呈增加趋势。经非条件logistic单因素及多因素回归分析,治疗时间2年及以上且小于5年组及≥5年组与<2年组分别比较,病毒完全抑制率差异均有统计学意义(P<0.001)。结论 2004—2014年上海市艾滋病病毒感染者及病人的抗病毒治疗效果显著。
Objective To evaluate the effectiveness of free highly active anti-retroviral therapy （HAART} for adult HIV/AIDS patients from 2004 to 2014 in Shanghai and to identify predictive factors that may influence HAART. Methods A retrospective analysis was made on 3 939 cases of HIV infected people and patients from the information system for the prevention and control of AIDS, who received HAART in 2004 - 2014 in Shanghai. Results Among 3 939 patients, 90.2% were males, and the mean age was 38.4 ± 12.5 years. EFV ＋ 3TC ＋ AZT was the most common regimen （ 35.8% ）. The mean CD4 ＋ T cell count was （ 199.2 ± 142.9 ）/mm3 at baseline while （ 457.2 ± 211.9 ）/mm3 after HARRT. Significant difference was found in CD4 ＋ T cell count between those at baseline and after HARRT, and with the group of females, there was longer treatment period, heterosexual transmission and baseline CD4 ＋ T cell count lower than 350 cells/mm3 with greater growth of CD4 ＋ T cell count. After HARRT, HIV viral loads in 93. 5% patients were below the detection limit. Non-conditional logistic regression analysis indicated that the length of treatment period affected the virological response of HAART. The longer the patient received HARRT, the greater virus inhibition effect they had. Conclusion From 2004 to 2014, the antiretroviral therapy for HIV/AIDS patients in Shanghai was obviously effective.
出处
《上海预防医学》
CAS
2015年第12期732-735,共4页
Shanghai Journal of Preventive Medicine
关键词
艾滋病
高效抗逆转录病毒治疗
病毒学应答
免疫学应答
影响因素
HIV/AIDS
Highly active anti-retroviral therapy
Virological response
Immunolog- ical response
Impact factors
